These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 9221983)

  • 1. Cenesthetic hallucinations in a patient with Parkinson's disease.
    Jiménez-Jiménez FJ; Ortí-Pareja M; Gasalla T; Tallón-Barranco A; Cabrera-Valdivia F; Fernández-Lliria A
    J Neurol Neurosurg Psychiatry; 1997 Jul; 63(1):120. PubMed ID: 9221983
    [No Abstract]   [Full Text] [Related]  

  • 2. Clozapine for psychosis in Parkinson's disease.
    Pfeiffer RF; Kang J; Graber B; Hofman R; Wilson J
    Mov Disord; 1990; 5(3):239-42. PubMed ID: 2388641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New medication recommended for Parkinson's disease.
    Levenson D
    Rep Med Guidel Outcomes Res; 2001 Jun; 12(13):7-9. PubMed ID: 12182172
    [No Abstract]   [Full Text] [Related]  

  • 4. Clozapine withdrawal symptoms in a Parkinson's disease patient.
    Zesiewicz TA; Borra S; Hauser RA
    Mov Disord; 2002 Nov; 17(6):1365-7. PubMed ID: 12465085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risperidone for hallucinations in levodopa-treated Parkinson's disease patients.
    Meco G; Alessandria A; Bonifati V; Giustini P
    Lancet; 1994 May; 343(8909):1370-1. PubMed ID: 7514254
    [No Abstract]   [Full Text] [Related]  

  • 6. Antidepressant use in treatment of psychosis with comorbid depression in Parkinson's disease.
    Meco G; Bernardi S
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):311-3. PubMed ID: 16919377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Behavioral indicators of hallucinosis in levodopa-treated Parkinson's disease.
    Glantz RH; Bieliauskas L; Paleologos N
    Adv Neurol; 1987; 45():417-20. PubMed ID: 3825719
    [No Abstract]   [Full Text] [Related]  

  • 8. Medical hazards of the internet: gambling in Parkinson's disease.
    Larner AJ
    Mov Disord; 2006 Oct; 21(10):1789. PubMed ID: 16941457
    [No Abstract]   [Full Text] [Related]  

  • 9. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
    Storch A; Trenkwalder C; Oehlwein C; Winkelmann J; Polzer U; Hundemer HP; Schwarz J
    Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hallucinations and confusion after pergolide withdrawal.
    McHale DM; Sage JI
    Clin Neuropharmacol; 1988 Dec; 11(6):545-8. PubMed ID: 3233591
    [No Abstract]   [Full Text] [Related]  

  • 11. [Hallucinations in Parkinson's disease].
    Moser A; Hagenah J; Kömpf D
    Nervenarzt; 2003 Apr; 74(4):376-85, quiz 385-6. PubMed ID: 12707709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pergolide: a useful agonist for the treatment of Parkinson disease].
    Bonnet AM; Houeto JL
    Rev Neurol (Paris); 2002 Jul; 158(6-7):744-5. PubMed ID: 12486908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pergolide and Parkinson's disease: new preparation. No clear benefit.
    Prescrire Int; 2000 Dec; 9(50):177-9. PubMed ID: 11475497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The use of clozapine and levodopa for the treatment of persistent visual hallucinations and parkinsonism in Lewy body dementia].
    Archie A; Persoons P; Vandenbulcke M
    Tijdschr Psychiatr; 2013; 55(4):287-91. PubMed ID: 23595844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clozapine for dopaminergic-induced paraphilias in Parkinson's disease.
    Fernandez HH; Durso R
    Mov Disord; 1998 May; 13(3):597-8. PubMed ID: 9613761
    [No Abstract]   [Full Text] [Related]  

  • 16. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients.
    Sa DS; Lang AE
    Neurology; 2001 Aug; 57(4):747. PubMed ID: 11524507
    [No Abstract]   [Full Text] [Related]  

  • 17. Pergolide for levodopa-induced complications in Parkinson's disease.
    Clarke C E; Speller J M
    Cochrane Database Syst Rev; 2000; (2):CD000235. PubMed ID: 10796704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching from pergolide to pramipexole in patients with Parkinson's disease.
    Hanna PA; Ratkos L; Ondo WG; Jankovic J
    J Neural Transm (Vienna); 2001; 108(1):63-70. PubMed ID: 11261747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L-DOPA therapy in advanced Parkinson's disease.
    Zoldan J; Friedberg G; Weizman A; Melamed E
    Adv Neurol; 1996; 69():541-4. PubMed ID: 8615178
    [No Abstract]   [Full Text] [Related]  

  • 20. Improvement of motor fluctuations in patients with Parkinson's disease following treatment with high doses of pergolide and cessation of levodopa.
    Schwarz J; Scheidtmann K; Trenkwalder C
    Eur Neurol; 1997; 37(4):236-8. PubMed ID: 9208264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.